

New Consultants Group 16th Annual Meeting

Vista Suite, [Crowne Plaza](#), Birmingham City Centre,
Birmingham B1 1HH

Saturday 17th – Sunday 18th March 2018

AGENDA

Saturday

- 12:00hrs Lunch and Registration
- 13:15hrs **Welcome and AGM Briefing**
Introduction to ACP NCG Committee, NCG and meeting objectives
Drs Jen Brown, Natalie Cook, Kai-Keen Shiu and Tania Tillett.
- 13.20hrs **Session 1 (Shape of Training):**
13.20hrs **Summary and Update on Shape of Training**
Dr Jackie Newby, Chair of Medical Oncology SAC
Dr Adam Januszewski, Senior ACP and RCP Trainee Representative
- 14:00hrs **Open forum discussion**
all
- 14:40hrs Tea and coffee and check-in
- 15:10hrs **Session 2 (Complaints):**
Dealing with Complaints
Dr Claire Macaulay, Medico Legal Adviser, MDU
- 16:30hrs **Session 3 (Profiling and Repurposing):**
16:30hrs **National Profiling Initiatives**
Dr Nirupa Murugaesu, Clinical Lead for Molecular Oncology, Genomics England
- 17:00hrs **Keynote Speech**
Professor Daniel Hochhauser, Kathleen Ferrier Professor of Medical Oncology, UCL
- 17:30hrs Close
- 19:00 Dinner
After-dinner speaker: Professor Daniel Hochhauser

Sunday

- 09:25hrs** **Session 4 (How to develop an effective Acute Oncology Service in the era of immunotherapy):**
- 09:30hrs** Chair: Dr Alison Young, Consultant Medical Oncologist, St James's Hospital, Leeds
Dr Sarbjit Clare, Consultant in Acute Medicine, City Hospital, Birmingham
Dr Louise Medley, Consultant Medical Oncologist, Torbay Hospital
Nikki Hunter, Immunotherapy CNS, Royal Marsden Hospital, London
Em Girling, Acute Oncology CNS, Royal United Hospitals, Bath
- 11.00hrs** Tea and coffee and checkout
- 11:30hrs** **Panel discussion – AO/IO**
- 12.30hrs** **NCG AGM and discussion about ACP AGM and future meetings**
- 13:00hrs** Lunch

This meeting has been submitted for approval by the Federation of the Royal Colleges of Physicians of the United Kingdom for 7 category 1 (external) credits (code 115699)

The educational content of the meeting is supported by Daiichi-Sankyo, Guardant Health, Lilly Oncology, MSD, Merck Serono, Pfizer, Roche and Tesaro, none of whom have had any input into the meeting agenda or content



MSD



MERCK

GUARDANTHEALTH

